Clinical Trial Update: Assessment of KAN-101 in Celiac Disease (ACeD) [Phase 1]

View source ↗

Summary

Phase 1 assessment of KAN-101 for celiac disease has been completed with results posted, sponsored by Kanyos Bio (a subsidiary of Anokion).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Celiac Disease

Drugs mentioned

• KAN-101

Snippet

Sponsor: Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA | Conditions: Celiac Disease | Phase 1 | Status: COMPLETED | Results posted: 2024-03-21